A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination with Durvalumab (MEDI4736) or Tremelimumab in Patients with Advanced Solid Tumors
||Eli Lilly and Company
||Male and Female Patients
|U.S. Govt. ID:
||Richard Carvajal MD: 212-305-7115 / email@example.com
The primary purpose of this study is to determine a safe dose for the combinations of LY3022855 with durvalumab or LY3022855 with tremelimumab. This study will help answer the following research questions- What side effects may be experienced when taking LY3022885 with durvalumab ortremelimumab and how much LY302255, in combination with durvalumab or tremelimumab, should be given to the research subjects/participants diagnosed with advanced solid tumors.
This study is closed
Richard Carvajal, MD
|Have you been diagnosed with advanced solid tumors?